Analyst William Plovanic of Canaccord Genuity reiterated a Buy rating on HeartFlow, Inc., boosting the price target to $43.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
William Plovanic has given his Buy rating due to a combination of factors, chiefly HeartFlow’s strong Q4 outperformance and what he views as overly cautious 2026 guidance. Revenue and adjusted net income exceeded both his and consensus estimates, supported by solid gross margins and disciplined operating expenses, while initial 2026 revenue guidance still implies healthy double-digit growth.
He also highlights Plaque Analysis as a key upside driver, with broad U.S. reimbursement already in place and expected to accelerate in the back half of 2026, alongside incremental margin benefits from its high-profit contribution. In addition, he points to multiple near-term catalysts, including new product launches such as PCI Navigator, expanded sales capacity funded by the IPO, and structural growth in CCTA procedure volumes, all of which support his view that management is positioned to deliver repeated beats and guidance raises.
According to TipRanks, Plovanic is a 3-star analyst with an average return of 1.2% and a 39.88% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as HeartFlow, Inc., TransMedics Group, and Atricure.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $38.00 price target.